Literature DB >> 15125983

The path from initial inquiry to initiation of treatment for social anxiety disorder in an anxiety disorders specialty clinic.

Meredith E Coles1, Cynthia L Turk, Lauri Jindra, Richard G Heimberg.   

Abstract

Efficacious treatments for social anxiety disorder have become increasingly available, with approximately three-quarters of treatment completers showing significant improvement [Arch. Gen. Psychiatry 55 (1998) 1133.]. However, very few individuals with social anxiety disorder access these services. The present study reports on the path to initiation of treatment for social anxiety disorder among individuals contacting an anxiety disorder specialty clinic. Of 395 initial telephone inquiries, only 60 individuals (15%) started treatment. Three "critical points" associated with high pretreatment attrition were identified: scheduling an initial interview, attending a scheduled initial interview, and initiating a treatment program after receiving a principal diagnosis of social anxiety disorder. Several demographic variables (e.g., level of education, race) were related to attendance at the initial interview. However, no differences were found between those who did and did not initiate treatment on demographic variables, symptom severity, or quality of life. Given that most individuals who complete treatment for social phobia experience significant benefit, results of the current study suggest that future efforts should be devoted to increasing number of patients who access these services.

Entities:  

Mesh:

Year:  2004        PMID: 15125983     DOI: 10.1016/S0887-6185(02)00259-1

Source DB:  PubMed          Journal:  J Anxiety Disord        ISSN: 0887-6185


  9 in total

1.  Failure and delay in treatment-seeking across anxiety disorders.

Authors:  Emily M Johnson; Meredith E Coles
Journal:  Community Ment Health J       Date:  2012-09-29

2.  Self-Disclosure and Mental Health Service Use in Socially Anxious Adolescents.

Authors:  Daniela Colognori; Petra Esseling; Catherine Stewart; Philip Reiss; Feihan Lu; Brady Case; Carrie Masia Warner
Journal:  School Ment Health       Date:  2012-12-01

3.  Interpretation training in individuals with generalized social anxiety disorder: a randomized controlled trial.

Authors:  Nader Amir; Charles T Taylor
Journal:  J Consult Clin Psychol       Date:  2012-01-16

4.  Attention training in individuals with generalized social phobia: A randomized controlled trial.

Authors:  Nader Amir; Courtney Beard; Charles T Taylor; Heide Klumpp; Jason Elias; Michelle Burns; Xi Chen
Journal:  J Consult Clin Psychol       Date:  2009-10

5.  Treatment modality preferences and adherence to group treatment for panic disorder with agoraphobia.

Authors:  Michel Perreault; Dominic Julien; Noé Djawn White; Claude Bélanger; André Marchand; Theodora Katerelos; Diana Milton
Journal:  Psychiatr Q       Date:  2014-06

6.  A review of studies concerning treatment adherence of patients with anxiety disorders.

Authors:  Lívia Santana; Leonardo F Fontenelle
Journal:  Patient Prefer Adherence       Date:  2011-08-23       Impact factor: 2.711

7.  Internet-based self-help therapy with FearFighter™ versus no intervention for anxiety disorders in adults: study protocol for a randomised controlled trial.

Authors:  Morten Fenger; Jane Lindschou; Christian Gluud; Per Winkel; Lise Jørgensen; Sten Kruse-Blinkenberg; Marianne Lau
Journal:  Trials       Date:  2016-10-28       Impact factor: 2.279

8.  Evaluation of the psychometric properties of a modified version of the Social Phobia Screening Questionnaire for use in adolescents.

Authors:  Malin Gren-Landell; Andreas Björklind; Maria Tillfors; Tomas Furmark; Carl Göran Svedin; Gerhard Andersson
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2009-11-11       Impact factor: 3.033

9.  Pretreatment attrition and formal withdrawal during treatment and their predictors: an exploratory study of the anxiety online data.

Authors:  Ali M Al-Asadi; Britt Klein; Denny Meyer
Journal:  J Med Internet Res       Date:  2014-06-17       Impact factor: 5.428

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.